{
    "id": "58508899",
    "text": "The Special Programme on Human Reproduction (HRP), also known as the Special Programme of Research, Development and Research Training in Human Reproduction, was a World Health Organization (WHO) endeavor.Benagiano, G., & Merialdi, M. (2011). Carl Djerassi and the World Health Organisation special programme of research in human reproduction. Journal f\u00fcr Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology, 8(1), 10-13. http://www.kup.at/kup/pdf/10163.pdf It resulted in the following marketed combined injectable contraceptives: * Estradiol cypionate/medroxyprogesterone acetate (EC/MPA; brand names Cyclofem, Lunelle; code names HRP-112, Cyclo-Provera) * Estradiol valerate/norethisterone enanthate (EV/NETE; brand name Mesigyna; code name HRP-102) And in the following never-marketed progestogen injectable contraceptives: * Levonorgestrel butanoate (LNG-B; code name HRP-002) * Levonorgestrel cyclobutylcarboxylate (code name HRP-001) * Levonorgestrel cyclopropylcarboxylate (code name HRP-003) ==See also== * Concept Foundation ==References== Category:Hormonal contraception Category:World Health Organization ",
    "title": "Special Programme on Human Reproduction"
}